
|Videos|August 9, 2018
Exploring Novel Agents to Target Pathways in Lymphoma
Author(s)Julie M. Vose, MD, MBA
Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.
Advertisement
Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.
While many patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, are able to be cured, there are still many patients that cannot be cured, and the reason is still unclear, Vose explains.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
4
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
5




















